Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial

Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial

ABSTRACT

Irritable bowel syndrome (IBS) is a significant global healthcare burden, and effective intervention is crucial. This study investigated the effectiveness and safety of Bacillus coagulans BCP92, a probiotic, in managing IBS symptoms.

METHODS

A randomized controlled trial with 100 participants assessed various parameters such as IBS severity, digestive and gastrointestinal symptom frequency, stool consistency, interleukin-6 levels, stress relief, and anxiety levels over 12 weeks.

RESULTS

B. coagulans BCP92 significantly improved IBS severity, gastrointestinal symptom frequency, and stool consistency compared to the control group. It also provided remarkable mental stress relief. Safety assessment revealed an excellent profile with no severe adverse events reported.

CONCLUSION

B. coagulans BCP92 is a promising therapeutic option for managing IBS, showing significant efficacy in alleviating symptoms and improving overall mental well-being. This approach foresees improved patient outcomes and individualized treatment plans.

PMID: 39093754 | DOI: 10.1097/MD.0000000000039134

Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research for clinicians. Streamlining operations in today’s healthcare environment is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance workflows, improve patient outcomes, and reduce paper routines. Learn more at aidevmd.com.